Managing Clonal Hematopoiesis in Patients With Solid Tumors
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
CH in the setting of cytopenias are at high risk of occult myeloid neoplasms and ultimate development of overt disease. It has been demonstrated that cases of CH with a VAF greater than or equal to 10%, multiple mutations, and spliceosome gene mutations have high positive predictive values (ranging from 0.86 to 1.0) for the presence of occult myeloid neoplasm among patients being evaluated for cytopenias. folate, haptoglobin, lactate dehydrogenase, vitamin B1, vitamin B6, vitamin B12, methylmalonic acid, and copper levels; prothrombin time or partial thromboplastin time; and international normalized ratio. Speci fi c for anemia, we suggest measuring the following: reticulocyte count, fl ow cytometry for paroxysmal nocturnal hemoglobinuria (if low haptoglobin and/or high lactate dehydrogenase in appropriate clinical context), serum protein electrophoresis, and serum immuno fi xation. Speci fi c for thrombocytopenia we suggest measuring immature platelet fraction. Speci fi c for neutropenia, we suggest measuring antineutrophil antibody level. ( ‡ ) For patients anticipated to have a poor prognosis ( , 6 to 12 months) from their primary solid tumor, we would not suggest further work-up for CH. (§) Monitoringintervalcan bedeterminedby thetreatingclinician,thoughwewouldsuggest3-to 12-monthevaluations(morefrequentlyfor patients receiving ongoing cytotoxic therapy, and less frequently for patients in long-term follow-up). Current guidelines recommend targeting a blood pressure less than 130/80 mm Hg, 36 lifestyle modi fi cations, and pharmacotherapy with a thiazide diuretic, calcium channel blocker, or angiotensin-converting enzyme inhibitor/angiotensin receptor blocker. Preclinical and clinical studies suggest statins have potent antiin fl ammatory effects, including suppression of interleukin-1 b release, 36 and should be prescribed to all patients with an estimated 10-year atherosclerotic CVD risk greater than 7.5%. 38,39 BM, bone marrow; CVD, cardiovascular disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Age-related clonal hematopoiesis associated with adverse outcomes
Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P. V., Mar, B. G., Lindsley, R. C., Mermel, C. H., Burtt, N., Chavez, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408617 · Cited by 4,841 · cited 2×
“001).(9,10) In these studies, the strength of the association between CH and CVD was comparable to well-validated traditional cardiovascular risk factors such as high cholesterol, smoking, and hypertension.”
ResultGenomic classification and prognosis in acute myeloid leukemia
Papaemmanuil, E., Gerstung, M., Bullinger, L., Gaidzik, V. I., Paschka, P., Roberts, N. D., Potter, N. E., Heuser, M., Thol, F., Bolli, N., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1516192 · Cited by 4,350 · cited 2×
“CH mutations generally occur at low frequencies in genes implicated in myeloid neoplasms such as DNMT3A, TET2, ASXL1, and TP53.(8) Aging is the strongest known risk factor for CH, with the prevalence increasing greatly with each decade of life.”
BackgroundSelf-citationStone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.002 · Cited by 3,845
Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence
Genovese, G., Kähler, A. K., Handsaker, R. E., Lindberg, J., Rose, S. A., Bakhoum, S. F., Chambert, K., Mick, E., Neale, B. M., Fromer, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409405 · Cited by 3,531
Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease
Jaiswal, S., Natarajan, P., Silver, A. J., Gibson, C. J., Bick, A. G., Shvartz, E., McConkey, M., Gupta, N., Gabriel, S., Ardissino, D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701719 · Cited by 2,683 · cited 2×
“001).(9,10) In these studies, the strength of the association between CH and CVD was comparable to well-validated traditional cardiovascular risk factors such as high cholesterol, smoking, and hypertension.”
BackgroundResultClonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
Steensma, D. P., Bejar, R., Jaiswal, S., Lindsley, R. C., Sekeres, M. A., Hasserjian, R. P., & Ebert, B. L. (2015) · Blood · doi:10.1182/blood-2015-03-631747 · Cited by 1,971
Self-citationHigh burden and pervasive positive selection of somatic mutations in normal human skin
Martincorena, I., Roshan, A., Gerstung, M., Ellis, P., Van Loo, P., McLaren, S., Wedge, D. C., Fullam, A., Alexandrov, L. B., Tubio, J. M., et al. (2015) · Science · doi:10.1126/science.aaa6806 · Cited by 1,770
The Age Distribution of Cancer and a Multi-stage Theory of Carcinogenesis
Armitage, P., & Doll, R. (1954) · British Journal of Cancer · doi:10.1038/bjc.1954.1 · Cited by 1,549
Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice
Fuster, J. J., MacLauchlan, S., Zuriaga, M. A., Polackal, M. N., Ostriker, A. C., Chakraborty, R., Wu, C.-L., Sano, S., Muralidharan, S., Rius, C., et al. (2017) · Science · doi:10.1126/science.aag1381 · Cited by 1,536
Cited by
The evolutionary dynamics and fitness landscape of clonal hematopoiesis
Watson, C. J., Papula, A. L., Poon, G. Y. P., Wong, W. H., Young, A. L., Druley, T. E., Fisher, D. S., & Blundell, J. R. (2020) · Science · doi:10.1126/science.aay9333 · Cited by 444
DiNardo, C. D., Erba, H. P., Freeman, S. D., & Wei, A. H. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00108-3 · Cited by 437
Libby (2019) · doi:10.1016/j.jacc.2019.06.007 · Cited by 247
Mayerhofer, E., Strecker, C., Becker, H., Georgakis, M. K., Uddin, M. M., Hoffmann, M. M., Nadarajah, N., Meggendorfer, M., Haferlach, T., Rosand, J., et al. (2023) · Stroke · doi:10.1161/strokeaha.122.041416 · Cited by 41
What To Tell Your Patient With Clonal Hematopoiesis And Why: Insights From Two Specialized Clinics
Steensma, D. P., & Bolton, K. L. (2020) · Blood · doi:10.1182/blood.2019004291 · Cited by 14
Self-citation
Metadata
- Authors
- Bolton, K. L., Gillis, N. K., Coombs, C. C., Takahashi, K., Zehir, A., Bejar, R., Garcia-Manero, G., Futreal, A., Jensen, B. C., Diaz, L. A., Gupta, D., Mantha, S., Klimek, V., Papaemmanuil, E., Levine, R., & Padron, E.
- Venue
- Journal of Clinical Oncology
- Published
- 2019-01-01
- Volume
- 37
- Issue
- 1
- Pages
- 7-11
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2899732591
- Cited by
- 87
- References
- 19
- FWCI
- 5.17
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Managing Clonal Hematopoiesis in Patients With Solid Tumors. https://app.cochat.ai/papers/10.1200/jco.18.00331
- The paper
- Bolton, K. L., Gillis, N. K., Coombs, C. C., Takahashi, K., Zehir, A., Bejar, R., Garcia-Manero, G., Futreal, A., Jensen, B. C., Diaz, L. A., Gupta, D., Mantha, S., Klimek, V., Papaemmanuil, E., Levine, R., & Padron, E. (2019). Managing Clonal Hematopoiesis in Patients With Solid Tumors. Journal of Clinical Oncology. https://doi.org/10.1200/jco.18.00331
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.